Baseline patient characteristics for Ref FL and each HRDE subset
| . | All patients, N = 433 . | Ref FL, n = 352 . | HRDE combined, n = 81 . | HRDE subsets . | HRDE vs Ref FL, P value . | ||
|---|---|---|---|---|---|---|---|
| FL24, n = 43 . | TFL early, n = 29 . | TFL late, n = 9 . | |||||
| Age at diagnosis, y | 60.5 | 60.4 | 61.1 | 59.6 | 63.2 | 61.4 | .65 |
| Male | 248/433 (57.3%) | 198/352 (56.3%) | 50/81 (61.7%) | 25/43 (58.1%) | 19/29 (65.5%) | 6/9 (66.7%) | .73 |
| ECOG PS ≥2 | 34/432 (7.9%) | 21/352 (6.0%) | 13/81 (16%) | 5/43 (11.6%) | 8/29 (27.6%) | 0/9 (0.0%) | <.001 |
| SUVmax median (IQR) | 11.4 (8.6-15.1) | 11.1 (8.6-14.6) | 12.1 (8.1-19.0) | 11.4 (7.4-16.5) | 16.3 (9.9-21.9) | 12.1 (10.5-15.6) | .070 |
| TMTV (cm3) (IQR) | 251.9 (79.3-738.5) | 187.4 (81.3-536.1) | 333 (138-1197) | 259.7 (103.5-872.1) | 1197 (740.8-1618) | _ | .12 |
| TLG (IQR) | 1402 (423.8-4752) | 1163 (311.5-3111) | 2209 (535-6702) | 1427 (380.4-6257) | 8606 (5515-11914) | _ | .085 |
| Stage III-IV | 358/432 (82.9%) | 286/352 (81.5%) | 72/81 (88.9%) | 39/43 (90.7%) | 26/29 (89.7%) | 7/9 (77.8%) | .31 |
| LDH elevated | 128/433 (29.6%) | 88/352 (25.0%) | 40/81 (49.4%) | 21/43 (48.8%) | 16/29 (55.2%) | 3/9 (33.3%) | <.001 |
| Age >60 y | 230/433 (53.1%) | 184/352 (52.3%) | 46/81 (56.8%) | 24/43 (55.8%) | 18/29 (62.1%) | 4/9 (44.4%) | .71 |
| >4 nodal sites | 241/432 (55.8%) | 197/352 (56.1%) | 44/81 (54.3%) | 26/43 (60.5%) | 14/29 (48.3%) | 4/9 (44.4%) | .68 |
| Hb <120 g/L | 58/432 (13.4%) | 45/352 (12.8%) | 13/81 (16.0%) | 6/43 (14.0%) | 7/29 (24.1%) | 0/9 (0.0%) | .25 |
| Histological grade 3A | 32/278 (11.5%) | 25/232 (10.8%) | 7/46 (15.2%) | 1/43 (4.5%) | 6/20 (30.0%) | 0/5 (0.0%) | .069 |
| BM involvement | 144/335 (43.0%) | 116 (41.4%) | 28/55 (50.9%) | 14/30 (46.7%) | 12/20 (60.0%) | 2/5 (40.0%) | .42 |
| B2M elevated | 67/242 (27.7%) | 48/202 (23.8%) | 19/40 (47.5%) | 7/19 (36.8%) | 11/16 (68.8%) | 1/5 (20.0%) | .001 |
| FLIPI group | |||||||
| Low (0-1) | 96/432 (22.2%) | 83/351 (23.6%) | 13/81 (16.0%) | 6/43 (14.0%) | 3/29 (10.3%) | 4/9 (44.4%) | .013 |
| Int (2) | 138/432 (31.9%) | 120/351 (34.2%) | 18/81 (22.2%) | 12/43 (27.9%) | 5/29 (17.2%) | 1/9 (11.1%) | |
| High (3-5) | 198/432 (45.8%) | 148/351 (42.2%) | 50/81 (61.7%) | 25/43 (58.1%) | 21/29 (72.4%) | 4/9 (44.4%) | |
| 1L therapy | |||||||
| Bendamustine | 272/433 (62.8%) | 227/352 (64.5%) | 45/81 (55.6%) | 21/43 (48.8%) | 19/29 (65.5%) | 5/9 (55.6%) | .29 |
| CHOP | 119/433 (27.5%) | 93/352 (26.4%) | 26/81 (32.1%) | 14/43 (32.6%) | 8/29 (27.6%) | 4/0 (44.4%) | |
| CVP | 42/433 (9.7%) | 32/352 (9.1%) | 10/81 (12.3%) | 8/43 (18.6%) | 2/29 (6.9%) | 0/9 (0.0%) | |
| CD20 MAb | |||||||
| Rituximab | 369 /433 (85.2%) | 293/352 (83.2%) | 76/81 (93.8%) | 41/43 (95.3%) | 26/29 (89.7%) | 9/9 (100.0%) | .095 |
| Obinutuzumab | 64/433 (14.8%) | 59/352 (16.8%) | 5/81 (6.2%) | 2/43 (4.7%) | 3/29 (10.3%) | 0/9 (0.0%) | |
| Maintenance therapy | 209/433 (48.3%) | 177/352 (50.3%) | 32/81 (39.5%) | 16/43 (37.2%) | 11/29 (37.9%) | 5/9 (55.6%) | .25 |
| Median follow-up from diagnosis y (range) | 5.2 y (0.6-20.5) | 5.09 y (2.1-19.1) | _ | 7.2 y (0.6-20.5) | 5.66 y (0.7-16.5) | 10.29 y (2.5-17.9) | _ |
| . | All patients, N = 433 . | Ref FL, n = 352 . | HRDE combined, n = 81 . | HRDE subsets . | HRDE vs Ref FL, P value . | ||
|---|---|---|---|---|---|---|---|
| FL24, n = 43 . | TFL early, n = 29 . | TFL late, n = 9 . | |||||
| Age at diagnosis, y | 60.5 | 60.4 | 61.1 | 59.6 | 63.2 | 61.4 | .65 |
| Male | 248/433 (57.3%) | 198/352 (56.3%) | 50/81 (61.7%) | 25/43 (58.1%) | 19/29 (65.5%) | 6/9 (66.7%) | .73 |
| ECOG PS ≥2 | 34/432 (7.9%) | 21/352 (6.0%) | 13/81 (16%) | 5/43 (11.6%) | 8/29 (27.6%) | 0/9 (0.0%) | <.001 |
| SUVmax median (IQR) | 11.4 (8.6-15.1) | 11.1 (8.6-14.6) | 12.1 (8.1-19.0) | 11.4 (7.4-16.5) | 16.3 (9.9-21.9) | 12.1 (10.5-15.6) | .070 |
| TMTV (cm3) (IQR) | 251.9 (79.3-738.5) | 187.4 (81.3-536.1) | 333 (138-1197) | 259.7 (103.5-872.1) | 1197 (740.8-1618) | _ | .12 |
| TLG (IQR) | 1402 (423.8-4752) | 1163 (311.5-3111) | 2209 (535-6702) | 1427 (380.4-6257) | 8606 (5515-11914) | _ | .085 |
| Stage III-IV | 358/432 (82.9%) | 286/352 (81.5%) | 72/81 (88.9%) | 39/43 (90.7%) | 26/29 (89.7%) | 7/9 (77.8%) | .31 |
| LDH elevated | 128/433 (29.6%) | 88/352 (25.0%) | 40/81 (49.4%) | 21/43 (48.8%) | 16/29 (55.2%) | 3/9 (33.3%) | <.001 |
| Age >60 y | 230/433 (53.1%) | 184/352 (52.3%) | 46/81 (56.8%) | 24/43 (55.8%) | 18/29 (62.1%) | 4/9 (44.4%) | .71 |
| >4 nodal sites | 241/432 (55.8%) | 197/352 (56.1%) | 44/81 (54.3%) | 26/43 (60.5%) | 14/29 (48.3%) | 4/9 (44.4%) | .68 |
| Hb <120 g/L | 58/432 (13.4%) | 45/352 (12.8%) | 13/81 (16.0%) | 6/43 (14.0%) | 7/29 (24.1%) | 0/9 (0.0%) | .25 |
| Histological grade 3A | 32/278 (11.5%) | 25/232 (10.8%) | 7/46 (15.2%) | 1/43 (4.5%) | 6/20 (30.0%) | 0/5 (0.0%) | .069 |
| BM involvement | 144/335 (43.0%) | 116 (41.4%) | 28/55 (50.9%) | 14/30 (46.7%) | 12/20 (60.0%) | 2/5 (40.0%) | .42 |
| B2M elevated | 67/242 (27.7%) | 48/202 (23.8%) | 19/40 (47.5%) | 7/19 (36.8%) | 11/16 (68.8%) | 1/5 (20.0%) | .001 |
| FLIPI group | |||||||
| Low (0-1) | 96/432 (22.2%) | 83/351 (23.6%) | 13/81 (16.0%) | 6/43 (14.0%) | 3/29 (10.3%) | 4/9 (44.4%) | .013 |
| Int (2) | 138/432 (31.9%) | 120/351 (34.2%) | 18/81 (22.2%) | 12/43 (27.9%) | 5/29 (17.2%) | 1/9 (11.1%) | |
| High (3-5) | 198/432 (45.8%) | 148/351 (42.2%) | 50/81 (61.7%) | 25/43 (58.1%) | 21/29 (72.4%) | 4/9 (44.4%) | |
| 1L therapy | |||||||
| Bendamustine | 272/433 (62.8%) | 227/352 (64.5%) | 45/81 (55.6%) | 21/43 (48.8%) | 19/29 (65.5%) | 5/9 (55.6%) | .29 |
| CHOP | 119/433 (27.5%) | 93/352 (26.4%) | 26/81 (32.1%) | 14/43 (32.6%) | 8/29 (27.6%) | 4/0 (44.4%) | |
| CVP | 42/433 (9.7%) | 32/352 (9.1%) | 10/81 (12.3%) | 8/43 (18.6%) | 2/29 (6.9%) | 0/9 (0.0%) | |
| CD20 MAb | |||||||
| Rituximab | 369 /433 (85.2%) | 293/352 (83.2%) | 76/81 (93.8%) | 41/43 (95.3%) | 26/29 (89.7%) | 9/9 (100.0%) | .095 |
| Obinutuzumab | 64/433 (14.8%) | 59/352 (16.8%) | 5/81 (6.2%) | 2/43 (4.7%) | 3/29 (10.3%) | 0/9 (0.0%) | |
| Maintenance therapy | 209/433 (48.3%) | 177/352 (50.3%) | 32/81 (39.5%) | 16/43 (37.2%) | 11/29 (37.9%) | 5/9 (55.6%) | .25 |
| Median follow-up from diagnosis y (range) | 5.2 y (0.6-20.5) | 5.09 y (2.1-19.1) | _ | 7.2 y (0.6-20.5) | 5.66 y (0.7-16.5) | 10.29 y (2.5-17.9) | _ |
P values obtained using Pearson χ2 test or Fisher exact test (if expected cell counts <1 in any cell or expected counts <5 in >20% of cells) for categorical variables and analysis of variance or Kruskal-Wallis analysis of variance for approximately normally distributed and nonnormally distributed continuous variables respectively. Continuous variables are reported as a median value.
BM, bone marrow; Hb, hemoglobin; Int, Intermediate; IQR, Interquartile range; MAb, monoclonal antibody; SUVmax, maximum standardized uptake value, 1L, frontline.